Canada markets closed

Bone Therapeutics SA (BNZPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.20000.0000 (0.00%)
At close: 10:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close4.2000
BidN/A x N/A
AskN/A x N/A
Day's Range4.2000 - 4.2000
52 Week Range4.2000 - 4.2600
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.6370
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Bone Therapeutics Provides Third Quarter 2021 Business Update

    REGULATED INFORMATION Recruitment ALLOB tibial fracture Phase IIb trial slower than anticipated due to pandemic No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment in Phase III knee osteoarthritis study First tranche of EUR 8.0 million of the EIB financing received Signing of research evaluation agreement with Implant Therapeutics as well as scientific advisory board appointments latest steps in creating new iMSC

  • GlobeNewswire

    Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development

    Gosselies, Belgium, 12 October 2021, 7:00 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed key experts to a Scientific Advisory Board (SAB). Bone Therapeutics has appointed the members of this SAB specifically to provide additional expert guidance on the development of Bone Therapeutics’ novel, next generation induced pluripotent stem cell-derived mesenchym

  • GlobeNewswire

    Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)

    REGULATED INFORMATION Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise iPSC technology allows for the development of next-generation cell therapy products as a key addition to Bone Therapeutic’s existing cell therapy platform Gosselies, Belgium and Beltsville, MA, US, 28 September 2021, 7.00 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in